Senate Panel Details Medtronic Role In Editing Out Negative Study Findings From Journal Article
This article was originally published in The Gray Sheet
A Medtronic employee urged leaving out adverse event details in a medical journal article on the firm's InFuse bone graft product, according to a Senate Finance Committee investigatory report.
You may also be interested in...
An agency official refused to say if the rule is imminent during a Sept. 12 roundtable discussion on Capitol Hill on the topic, and would not even confirm that the central data-collection requirements for device and drug companies would begin in 2013.
The Yale physician behind Medtronic’s recent decision to hand over all of its raw data on the embattled Infuse spinal bone graft for independent analyses and ultimate release to the broader research community sees the development as not only a smart decision for Medtronic but also as a major step forward in creating a model for the device and drug industries.
Nanosphere antiplatelet gene test “not approvable”